IP Library Granted Patent US 11,691,976
Granted Patent B2
US 11,691,976 · App. 16/548,214 · Granted Jul 4, 2023

Coelenterazine analogues

Inventors: Joel R. Walker (San Luis Obispo, CA); Thomas A. Kirkland (Atascadero, CA); Wenhui Zhou (San Luis Obispo, CA); Mary P. Hall (Waunakee, WI); Harry Tetsuo Uyeda (Los Osos, CA)
Assignee: Promega Corporation
C07D487/04A61K49/0021G01N21/763
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,691,976
App. No.
16/548,214
Granted
Jul 4, 2023
Kind
B2
Abstract

Described are coelenterazine analogues, methods for making the analogues, kits comprising the analogues, and methods of using the compounds for the detection of luminescence in luciferase-based assays.

Claims (47)

1. A compound of formula (II)

or a tautomer or a salt thereof, wherein:

Y is nitro, or —NR y1 R y2 ;

p is 0, 1, 2, 3, or 4;

q is 0, 1, 2, 3, 4, or 5;

p+q is 1, 2, 3, 4, 5, 6, 7, 8, or 9;

R 3 , at each occurrence, is independently halogen, CN, nitro, C 1-10 alkyl, C 1-10 haloalkyl, —OR A3 , or —NR B3 R C3 ;

R 4 , at each occurrence, is independently halogen, CN, nitro, C 1-10 alkyl, C 1-10 haloalkyl, —OR A4 , or —NR B4 R C4 ;

R A3 and R A4 , at each occurrence, are independently H, C 1-10 haloalkyl, C 3-12 cycloalkyl, —C(O)C 1-10 alkyl, —C(O)C 3-12 cycloalkyl, or —C(O)C 1-3 alkylene-C 3-12 cycloalkyl, wherein each cycloalkyl is optionally substituted with 1-4 substituents independently selected from the group consisting of halogen, C 1-4 alkyl, and C 1-4 haloalkyl;

R B3 , R B4 , R C3 , and R C4 , at each occurrence, are independently H, C 1-10 haloalkyl, C 3-12 cycloalkyl, —C(O)C 1-10 alkyl, —C(O)C 3-12 cycloalkyl, —C(O)C 1-3 alkylene-C 3-12 cycloalkyl, —SO 2 C 1-10 alkyl, —SO 2 C 3-12 cycloalkyl, or —SO 2 C 1-3 alkylene-C 3-12 cycloalkyl, wherein each cycloalkyl is optionally substituted with 1-4 substituents independently selected from the group consisting of halogen, C 1-4 alkyl, and C 1-4 haloalkyl;

alternatively, R B3 and R C3 and/or R B4 and R C4 , together with the nitrogen atom to which each attaches form a 4- to 8-membered saturated or partially unsaturated heterocyclic ring, optionally substituted with 1-4 substituents independently selected from the group consisting of C 1-4 alkyl, C 1-4 haloalkyl, oxo, —OH, and —OC 1-4 alkyl;

R y1 and R y2 , at each occurrence, are independently H, C 1-10 alkyl, C 1-10 haloalkyl, C 3-12 cycloalkyl, or —C 1-3 alkylene-C 3-12 cycloalkyl, wherein each cycloalkyl is optionally substituted with 1-4 substituents independently selected from the group consisting of halogen, C 1-4 alkyl, and C 1-4 haloalkyl; and

alternatively, R y1 and R y2 together with the nitrogen atom to which each attaches form a 4- to 8-membered saturated or partially unsaturated heterocyclic ring, optionally substituted with 1-4 substituents independently selected from the group consisting of C 1-4 alkyl, C 1-4 haloalkyl, oxo, —OH, and —OC 1-4 alkyl.

2. The compound of claim 1 , or a tautomer or a salt thereof, wherein q is 0, 1, or 2.

3. The compound of claim 1 , or a tautomer or a salt thereof, wherein R y1 and R y2 are H.

4. The compound of claim 1 , or a tautomer or a salt thereof, wherein p+q is 1 or 2.

5. The compound of claim 1 , or a tautomer or a salt thereof, wherein p is 1 and R 3 is halogen.

6. The compound of claim 5 , or a tautomer or salt thereof, wherein R 3 is fluorine.

7. The compound of claim 1 , or a tautomer or salt thereof, wherein R 4 , at each occurrence, is halogen.

8. The compound of claim 7 , or a tautomer or a salt thereof, wherein the halogen is fluorine.

9. The compound of claim 1 , or a tautomer or salt thereof, wherein q is 1 or 2 and R 4 is fluorine.

10. The compound of claim 1 , or a tautomer or a salt thereof, wherein q is 1 and R 4 is C 1-10 alkyl.

11. The compound of claim 1 , or a tautomer or salt thereof, selected from the group consisting of:

12. A kit comprising the compound of claim 1 , or a tautomer or a salt thereof.

13. A method for detecting luminescence in a sample, the method comprising

contacting a sample with the compound of claim 1 , or a tautomer or a salt thereof;

contacting the sample with a coelenterazine-utilizing luciferase, if it is not present in the sample; and

detecting luminescence.

14. A method for detecting luminescence in a transgenic animal comprising

administering the compound of claim 1 , or a tautomer or a salt thereof, to a transgenic animal; and

detecting luminescence;

wherein the transgenic animal expresses a coelenterazine-utilizing luciferase.

15. The compound of claim 1 , or a tautomer or a salt thereof, wherein:

Y is nitro, or NR y1 R y2 ;

p is 0, 1, or 2;

q is 0, 1, or 2;

p+q is 1 or 2;

R 3 , at each occurrence, is independently halogen or C 1-4 alkyl; and

R 4 , at each occurrence, is independently halogen or C 1-4 alkyl.

16. The compound of claim 15 , or a tautomer or a salt thereof, wherein:

p is 0 or 1;

Y is NR y1 R y2 ;

R y1 and R y2 are H;

R 3 , at each occurrence, is independently fluorine or methyl; and

R 4 , at each occurrence, is independently fluorine or methyl.

17. A compound of formula:

or a tautomer or salt thereof.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 27, 2020
From: WALKER, JOEL R.; KIRKLAND, THOMAS A.; ZHOU, WENHUI; HALL, MARY P.; UYEDA, HARRY TETSUO
To: PROMEGA CORPORATION
Reel/Frame 051630/0354 →